Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys

The SARS-CoV-2 Omicron variant has very high levels of transmission, is resistant to neutralization by authorized therapeutic human monoclonal antibodies (mAb) and is less sensitive to vaccine-mediated immunity. To provide additional therapies against Omicron, we isolated a mAb named P2G3 from a pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenwick, Craig, Turelli, Priscilla, Ni, Dongchun, Perez, Laurent, Lau, Kelvin, Herate, Cécile, Marlin, Romain, Lana, Erica, Pellaton, Céline, Raclot, Charlène, Esteves-Leuenberger, Line, Campos, Jérémy, Farina, Alex, Fiscalini, Flurin, Dereuddre-Bosquet, Nathalie, Relouzat, Francis, Abdelnabi, Rana, Foo, Caroline S., Neyts, Johan, Leyssen, Pieter, Lévy, Yves, Pojer, Florence, Stahlberg, Henning, LeGrand, Roger, Trono, Didier, Pantaleo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418005/
https://www.ncbi.nlm.nih.gov/pubmed/35879526
http://dx.doi.org/10.1038/s41564-022-01198-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418005/
https://www.ncbi.nlm.nih.gov/pubmed/35879526
http://dx.doi.org/10.1038/s41564-022-01198-6

Ejemplares similares